



IFW

I hereby Certify that this Correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Commissioner for Patents, Alexandria, VA 22313, on 04 August 2004.

M. Bud Nelson
Name MB Nelson
Signature 04 August 2004
Date of Signature

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: John Dwyer & Mary K. Delmedico

Application No. 10/671,316

Examiner:

Filed: 24 September 2003

Art Unit

For: Method for production of antivirals by use of HIV-derived HR1 peptides, trimers formed therefrom

Commissioner for Patents
Alexandria, VA

Docket No. TRM-002

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
37 CFR 1.56 and 1.97(b)(3)

Applicants wish to make of record the following reference under the provisions of 37 CFR 1.56 and 1.97(b)(3) and to provide a copy of relevant background with respect to the application. The submission of any document herewith is not intended as an admission that such document constitutes prior art against the claims of the present application, or is to be considered material to patentability as defined in 37 CFR \$1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove any document as a cited reference against the claims of the present invention.

References Cited

Please see attached Form PTO-1449 for list of publications, legible copies of all publication listed are enclosed.


Statement of Relevancy

Non Patent Literature Documents

1. Lu et al. (J. Virol. 2001 75:11146-11156); and Liu et al. (Biochemistry 2001 40:2797-2807) disclose gp41 ectodomain proteins (N-terminal peptide-linker-C-terminal peptide) each with an amino acid substitution (alanine- Lu et al.; threonine- Liu et al.) in the N-terminal portion of the gp41 ectodomain protein.
2. Eckert and Kim (PNAS 2001 98:11187-11192) discloses GCN4-HIV N-terminal peptide fusion proteins.

3. Ferrer et al. (*Nat. Struct. Biol.* 1999 6:953-960) discloses screening with a GCN4-HIV N-terminal peptide fusion protein.

Respectfully submitted,



M. Bud Nelson
Reg. No. 35,300
Attorney for the Applicants

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

AUG 06 2004

Docket Number (Optional)

TRM-002

Application Number

10/671,316

Applicant(s)

Dwyer & Delmedico

Filing Date

09/24/2003

Group Art Unit

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

U.S. PATENT APPLICATION PUBLICATIONS

*EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
							YES	NO

OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, Etc.)

		Liu et al., "Structural and Functional Analysis of the HIV gp41 Core Containing an Ile573 to Thr Substitution..." Biochemistry, 2001, 40:2797-2807.
		Lu et al., "Structural and Functional Analysis of Interhelical Interactions of the Human Immunodeficiency Virus Type 1 gp 41 Envelope...."; J. Virology, 2001, 75:11146-11156.
		Eckert & Kim, "Design of potent inhibitors of HIV-1 entry from the gp41 N-peptide region"; PNAS, 2001, 98:11187-11192.
		Ferrer et al., "Selection of gp41-mediated HIV-1 cell entry inhibitors from biased combinatorial libraries...."; Nature Structural Biology, 1999, 6:953-960.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.